BioTime, Inc. (NYSE Amex-listed BTIM) visits the NYSE. In honor of the occasion, President and CEO Michael D. West, Ph.D. rings The Opening Bell®.
|
|
|
You can also download this bell to your desktop:
1. Right-click on the download link
2. Select "Save Target As"
3. Select download location and save.
|
About BioTime, Inc.
BioTime, Inc. is a biotechnology company focused on stem cell technology and regenerative medicine. Its technologies include ACTCellerateTM that allows the generation of over 140 purified cell types from human embryonic stem cells, and ReCyteTM, a technology for generation of patient-specific stem cells to address the problem of transplant rejection. BioTime’s business has been largely focused on near-term revenue generation through the marketing of its first FDA approved synthetic blood plasma volume expander product Hextend®, and more recently through the marketing of stem cell products in the research product markets through its subsidiary Embryome Sciences, Inc. Stem cell products for research purposes generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. BioTime also plans to develop therapeutic applications of stem cell technology through two new subsidiaries, BioTime Asia, Limited, and OncoCyte Corporation.
|
